Get the Stockscreener App
3.07
3.15%
-0.10
Neurosense Therapeutics Ltd stock is traded at $3.07, with a volume of 9,704.
It is down -3.15% in the last 24 hours and down -52.70% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$3.17
Open:
$3.06
24h Volume:
9,704
Relative Volume:
0.55
Market Cap:
$5.82M
Revenue:
Net Income/Loss:
$-10.21M
P/E Ratio:
-5.255
EPS:
-0.5842
Net Cash Flow:
$-4.10M
1W Performance:
-16.12%
1M Performance:
-52.70%
6M Performance:
-78.32%
1Y Performance:
-87.42%
1-Day Range:
$3.06
$3.24
1-Week Range:
$2.87
$3.784
52-Week Range:
$2.87
$26.64
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
3.07 | 5.82M | 0 | -10.21M | -4.10M | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
$1 bid-price compliance regained, but NeuroSense (Nasdaq: NRSN) still faces a listing deficiency. - Stock Titan
The $1 share-price rule is met, but NeuroSense still faces another Nasdaq listing test. - Stock Titan
NRSN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 7.14%Earnings Forecast Report - https://www.dars.gov.et/
NeuroSense Regains Nasdaq Bid Price Compliance, Appeals Market Value Delisting Notice - The Globe and Mail
The $1 bid-price hurdle is cleared, but NeuroSense (Nasdaq: NRSN) still faces delisting. - Stock Titan
NeuroSense Provides Update on Nasdaq Listing Compliance - Moomoo
A $35 million Nasdaq market-value rule remains unmet; NeuroSense plans to seek more time. - Stock Titan
NeuroSense Provides Update on Nasdaq Listing Compliance - TradingView
Without delays, cash won't fund 12 months under NeuroSense's (NASDAQ: NRSN) original development plan. - Stock Titan
NeuroSense Provides Business Update and Progress for the First Half of 2026 - Morningstar
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - The Globe and Mail
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - The Globe and Mail
NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq - TipRanks
12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com
NeuroSense (NASDAQ: NRSN) cuts share count to 1.9M in 1-for-20 split - Stock Titan
NRSN 6-K & SEC Filings - Yahoo! Finance Canada
Why Is NeuroSense (NASDAQ:NRSN) in Focus Before Tuesday’s Open? - kalkinemedia.com
Amyotrophic Lateral Sclerosis Pipeline 2026: FDA Approvals, - openPR.com
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Parabolic SAR - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Trade Entry Signals - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips 1.24% to $0.41, Hovering Near Key Support at $0.39Ascending Triangle - dars.gov.et
NRSN Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - Morningstar
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - TipRanks
NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - Benzinga
NeuroSense (NRSN) gains 12‑month mandate for reverse share split - Stock Titan
NeuroSense Therapeutics Ltd. Warrant (NRSNW) Peer Comparison – Compare with Others - Value Research
NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - vinanet.vn
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session: Support at $0.36 and Resistance at $0.40 Frame the Range for the Current SessionValue Area High - careplusvn.com
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session: Support at $0.36 and Resistance at $0.40 Frame the Range for the Current SessionThrowback Trade - siam.in
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - dars.gov.et
NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - dars.gov.et
Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail
Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com
NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - TipRanks
NeuroSense Issues CEO Letter to Shareholders - Nasdaq
NeuroSense Issues CEO Letter to Shareholders - webull.com
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et
NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorAnchored VWAP - dars.gov.et
Global Neurodegenerative Disease Market is Expected to - GlobeNewswire
NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47PCR Moving Average - dars.gov.et
NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47Price Surge Stocks - dars.gov.et
NRSN Q2 2025 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Pipeline AdvancesMid-Term Outlook - dars.gov.et
NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus
Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurosense Therapeutics Ltd Stock (NRSN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ben-Noon Alon | Chief Executive Officer |
Jun 16 '26 |
Buy |
0.80 |
250,000 |
200,000 |
4,534,233 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):